400 related articles for article (PubMed ID: 30541581)
41. [Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy].
Wu X; Wen S; Zhu X; Yuan S; Xu X; Yang D; Sun L; Liu H; Liu F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):395-399. PubMed ID: 28490696
[TBL] [Abstract][Full Text] [Related]
42. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
43. Association of anti-phospholipasea2-receptor antibodies with clinical course of idiopathic membranous nephropathy.
Thokhonelidze I; Maglakelidze N; Sarishvili N; Kasradze T; Dalakishvili K
Georgian Med News; 2015 Apr; (241):49-53. PubMed ID: 25953939
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
45. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
Bobart SA; De Vriese AS; Pawar AS; Zand L; Sethi S; Giesen C; Lieske JC; Fervenza FC
Kidney Int; 2019 Feb; 95(2):429-438. PubMed ID: 30665573
[TBL] [Abstract][Full Text] [Related]
46. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological Characteristics and Outcomes of PLA
Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
[TBL] [Abstract][Full Text] [Related]
48. Retrospective analysis of
Guo Y; Guo N; Wang J; Wang R; Tang L
Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.
Dai H; Zhang H; He Y
Sci Rep; 2015 Mar; 5():8803. PubMed ID: 25740009
[TBL] [Abstract][Full Text] [Related]
50. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt HO; Tomas NM; Helmchen U; Panzer U; Stahl RA
Nephrol Dial Transplant; 2015 Nov; 30(11):1862-9. PubMed ID: 26142398
[TBL] [Abstract][Full Text] [Related]
51. Circulating antibodies to α-enolase and phospholipase A
Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
[TBL] [Abstract][Full Text] [Related]
52. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
53. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
54. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.
Choi JY; Kim DK; Kim YW; Yoo TH; Lee JP; Chung HC; Cho KH; An WS; Lee DH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH
J Korean Med Sci; 2018 Feb; 33(9):e74. PubMed ID: 29441742
[TBL] [Abstract][Full Text] [Related]
55. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
Gupta G; Fattah H; Ayalon R; Kidd J; Gehr T; Quintana LF; Kimball P; Sadruddin S; Massey HD; Kumar D; King AL; Beck LH
Clin Transplant; 2016 Apr; 30(4):461-9. PubMed ID: 26854647
[TBL] [Abstract][Full Text] [Related]
56. Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy.
Li X; Wei D; Zhou Z; Wang B; Xu Y; Pan J; Yang C; Lu J; Qiu Y
Med Sci Monit; 2016 May; 22():1630-6. PubMed ID: 27179439
[TBL] [Abstract][Full Text] [Related]
57. Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy.
Chen P; Shi SF; Qu Z; Zhao N; Xie XF; Lv JC; Liu LJ; Zhang H
Ren Fail; 2018 Nov; 40(1):213-218. PubMed ID: 29619862
[TBL] [Abstract][Full Text] [Related]
58. Clinical and pathological features of idiopathic membranous nephropathy in young people.
Lin C; Zheng D; Wang Y; Wang S
Nephrology (Carlton); 2019 Jun; 24(6):599-604. PubMed ID: 30175519
[TBL] [Abstract][Full Text] [Related]
59. PLA2R antibody, PLA2R rs4664308 polymorphism and PLA2R mRNA levels in Tunisian patients with primary membranous nephritis.
Dhaouadi T; Abdellatif J; Trabelsi R; Gaied H; Chamkhi S; Sfar I; Goucha R; Ben Hamida F; Ben Abdallah T; Gorgi Y
PLoS One; 2020; 15(10):e0240025. PubMed ID: 33002091
[TBL] [Abstract][Full Text] [Related]
60. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
